Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin reuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor

Abstract

A subject-matter of the present invention is pharmaceutical compositions comprising, in combination, at least one active ingredient chosen from (S)-(−)-N-[4-(4-acetamido-4-phenylpiperidin-1-yl)-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide and pharmaceutically acceptable salts there and at least one second active ingredient chosen from selective serotonin reuptake inhibitors, serotonin/norepinephrine reuptake inhibitors and pharmaceutically acceptable salts thereof.

1 . A pharmaceutical composition comprising, in combination, at least one active ingredient chosen from saredutant and pharmaceutically acceptable salts thereof and at least one second active ingredient chosen from selective serotonin reuptake inhibitors, serotonin/norepinephrine reuptake inhibitors, and pharmaceutically acceptable salts thereof, further in combination with at least one pharmaceutically acceptable excipient.  
   
   
       2 . The composition according to  claim 1 , wherein the at least one active ingredient is chosen from saredutant and pharmaceutically acceptable salts thereof and the at least one second active ingredient is chosen from selective serotonin reuptake inhibitors and pharmaceutically acceptable salts thereof.  
   
   
       3 . The composition according to  claim 2 , wherein the selective serotonin reuptake inhibitors are chosen from fluoxetine, citalopram, sertraline, fluvoxamine and pharmaceutically acceptable salts thereof.  
   
   
       4 . The composition according to  claim 2 , wherein the selective serotonin reuptake inhibitors are chosen from fluoxetine and pharmaceutically acceptable salts thereof.  
   
   
       5 . The composition according to  claim 2 , wherein the selective serotonin reuptake inhibitors are chosen from citalopram and pharmaceutically acceptable salts thereof.  
   
   
       6 . The composition according to  claim 2 , wherein the selective serotonin reuptake inhibitors are chosen from sertraline and pharmaceutically acceptable salts thereof.  
   
   
       7 . The composition according to  claim 2 , wherein the selective serotonin reuptake inhibitors are chosen from fluvoxamine and pharmaceutically acceptable salts thereof.  
   
   
       8 . The composition according to  claim 1 , wherein the at least one active ingredient is chosen from saredutant and pharmaceutically acceptable salts thereof and the at least one second active ingredient is chosen from serotonin/norepinephrine reuptake inhibitors and pharmaceutically acceptable salts thereof.  
   
   
       9 . The composition according to  claim 8 , wherein the serotonin/norepinephrine reuptake inhibitors are chosen from venlafaxine, duloxetine, milnacipran and pharmaceutically acceptable salts thereof.  
   
   
       10 . The composition according to  claim 8 , wherein the serotonin/norepinephrine reuptake inhibitors are chosen from venlafaxine and pharmaceutically acceptable salts thereof.  
   
   
       11 . The composition according to  claim 8 , wherein the serotonin/norepinephrine reuptake inhibitors are chosen from duloxetine and pharmaceutically acceptable salts thereof.  
   
   
       12 . The composition according to  claim 8 , wherein the serotonin/norepinephrine reuptake inhibitors are chosen from milnacipran and pharmaceutically acceptable salts thereof.  
   
   
       13 . A combination of at least one active ingredient chosen from saredutant and pharmaceutically acceptable salts thereof and at least one second active ingredient chosen from selective serotonin reuptake inhibitors, serotonin/norepinephrine reuptake inhibitors and pharmaceutically acceptable salts thereof.  
   
   
       14 . The combination according to  claim 13 , wherein the selective serotonin reuptake inhibitors are chosen from fluoxetine, citalopram, sertraline, fluvoxamine and pharmaceutically acceptable salts thereof.  
   
   
       15 . The combination according to  claim 13 , wherein the serotonin/norepinephrine reuptake inhibitors are chosen from venlafaxine, duloxetine, milnacipran and pharmaceutically acceptable salts thereof.  
   
   
       16 . A method of treatment of a mood disorder in a patient comprising administering to the patient a therapeutically effective amount of a combination of at least one active ingredient chosen from saredutant and pharmaceutically acceptable salts thereof and at least one second active ingredient chosen from selective serotonin reuptake inhibitors, serotonin/norepinephrine reuptake inhibitors and pharmaceutically acceptable salts thereof and optionally in combination with one or more pharmaceutically acceptable excipients.  
   
   
       17 . The method according to  claim 16 , wherein the at least one active ingredient is chosen from saredutant and pharmaceutically acceptable salts thereof and is administered in combination with at least one second active ingredient chosen from selective serotonin reuptake inhibitors and pharmaceutically acceptable salts thereof.  
   
   
       18 . The method according to  claim 18 , wherein the selective serotonin reuptake inhibitors are chosen from fluoxetine, citalopram, sertraline, fluvoxamine and pharmaceutically acceptable salt thereof.  
   
   
       19 . The method according to  claim 16 , wherein the at least one active ingredient is chosen from saredutant and pharmaceutically acceptable salts thereof and is administered in combination with at least one second active ingredient chosen from serotonin/norepinephrine reuptake inhibitors and pharmaceutically acceptable salts thereof.  
   
   
       20 . The method according to  claim 19 , wherein the serotonin/norepinephrine reuptake inhibitors are chosen from venlafaxine, duloxetine, milnacipran and pharmaceutically acceptable salts thereof.  
   
   
       21 . The method according to  claim 16 , wherein the mood disorder is major depressive disorder.  
   
   
       22 . The method according to  claim 21 , wherein the major depressive disorder is sexual dysfunctions associated with a major depressive disorder.  
   
   
       23 . The method according to  claim 16 , wherein the mood disorder is resistant depressive disorder.  
   
   
       24 . The method according to  claim 16 , wherein the mood disorder is dysthymic disorder.  
   
   
       25 . The method according to  claim 16 , wherein the mood disorder is depressive disorder not otherwise specified.  
   
   
       26 . The method according to  claim 16 , wherein the mood disorder is bipolar I disorder.  
   
   
       27 . The method according to  claim 16 , wherein the mood disorder is bipolar II disorder.  
   
   
       28 . The method according to  claim 16 , wherein the mood disorder is cyclothymic disorder.  
   
   
       29 . The method according to  claim 16 , wherein the mood disorder is bipolar disorder not otherwise specified.  
   
   
       30 . The method according to  claim 16 , wherein the mood disorder is mood disorder due to a general medical condition.  
   
   
       31 . The method according to  claim 16 , wherein the mood disorder is mood disorder induced by a substance.  
   
   
       32 . The method according to  claim 16 , wherein the mood disorder is mood disorder not otherwise specified.  
   
   
       33 . A method of treatment of an anxiety disorder in a patient comprising administering to the patient a therapeutically effective amount of a combination of at least one active ingredient chosen from saredutant and pharmaceutically acceptable salts thereof and at least one second active ingredient chosen from selective serotonin reuptake inhibitors, serotonin/norepinephrine reuptake inhibitors and pharmaceutically acceptable salts thereof optionally in combination with one or more pharmaceutically acceptable excipients.  
   
   
       34 . The method according to  claim 33 , wherein the at least one active ingredient is chosen from saredutant and pharmaceutically acceptable salts thereof and is administered in combination with at least one second active ingredient chosen from selective serotonin reuptake inhibitors and pharmaceutically acceptable salts thereof.  
   
   
       35 . The method according to  claim 34 , wherein the selective serotonin reuptake inhibitors are chosen from fluoxetine, citalopram, sertraline, fluvoxamine and pharmaceutically acceptable salts thereof.  
   
   
       36 . The method according to  claim 33 , wherein the at least one active ingredient is chosen from saredutant and pharmaceutically acceptable salts thereof and is administered in combination with at least one second active ingredient chosen from serotonin/norepinephrine reuptake inhibitors and pharmaceutically acceptable salts thereof.  
   
   
       37 . The method according to  claim 36 , wherein the serotonin/norepinephrine reuptake inhibitor is chosen from venlafaxine, duloxetine, milnacipran and pharmaceutically acceptable salts thereof.  
   
   
       38 . The method according to  claim 33 , wherein the anxiety disorder is panic attack.  
   
   
       39 . The method according to  claim 33 , wherein the anxiety disorder is agoraphobia.  
   
   
       40 . The method according to  claim 33 , wherein the anxiety disorder is social phobia.  
   
   
       41 . The method according to  claim 33 , wherein the anxiety disorder is obsessive-compulsive disorder.  
   
   
       42 . The method according to  claim 33 , wherein the anxiety disorder is post-traumatic stress condition.  
   
   
       43 . The method according to  claim 33 , wherein the anxiety disorder is acute stress condition.  
   
   
       44 . The method according to  claim 33 , wherein the anxiety disorder is generalized anxiety disorder.  
   
   
       45 . The method according to  claim 33 , wherein the anxiety disorder is anxiety disorder induced by a substance.